Skip to main content
Erschienen in: Der Kardiologe 6/2016

18.11.2016 | Koronare Herzerkrankung | Leitlinien

Kommentar zu den „2014 ESC/EACTS Guidelines on Myocardial Revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS)

verfasst von: Prof. Dr. A. Kastrati, S. Baldus, J. Cremer, V. Falk, C. W. Hamm, F.-J. Neumann, H. Schunkert, A. Welz

Erschienen in: Die Kardiologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Leitlinien von 2014 befassen sich in besonderem Maß mit Entscheidungsprozessen bei der Behandlung von Patienten mit koronarer Herzerkrankung. In den aktuellen Leitlinien wird erneut die Wichtigkeit von Notfall- und dringlichen Revaskularisationen bei Patienten mit akutem ST-Streckenhebungsinfarkt oder akutem Koronarsyndrom ohne ST-Streckenhebung unterstrichen. Der Entscheidungsprozess ist demgegenüber bei Patienten mit stabiler koronarer Herzerkrankung aufgrund verschiedener zur Verfügung stehender Behandlungsmöglichkeiten eine größere Herausforderung. Tatsächlich haben patientenbezogene Faktoren einen starken Einfluss auf Entscheidungsprozesse insbesondere in Fällen, in denen die aktuelle Evidenz keinen klaren Überlebensvorteil für die eine oder andere Behandlungsoption bietet. Essenzieller Bestandteil des multidisziplinären Ansatzes ist das „Herzteam“, bestehend hauptsächlich aus nichtinvasiv tätigen und interventionellen Kardiologen sowie Herzchirurgen. Abgesehen von patientenindividuellen Heart-Team-Diskussionen sehen die Leitlinien aus 2014 weiterhin vor, dass Standardsituationen auf der Basis institutioneller Protokolle bearbeitet werden können. In diesen Protokollen ist festzulegen, welche Patienten in der regelmäßigen Heart-Team-Konferenz besprochen werden und für welche Patienten ein Ad-hoc-Treffen des Heart-Teams stattfinden sollte. Die „hausinternen“ Protokolle sollen nicht ausschließlich auf den aktuellen Erkenntnissen und Ergebnissen der Leitlinien zur myokardialen Revaskularisation basieren, sondern sich auch an der spezifischen Erfahrung und den Stärken der interventionellen, kardiologischen und herzchirurgischen Abteilungen vor Ort orientieren.
Literatur
1.
Zurück zum Zitat Head SJ, Kieser TM, Falk V, Huysmans HA, Kappetein AP (2013) Coronary artery bypass grafting: Part 1 – the evolution over the first 50 years. Eur Heart J 34:2862–2872CrossRefPubMed Head SJ, Kieser TM, Falk V, Huysmans HA, Kappetein AP (2013) Coronary artery bypass grafting: Part 1 – the evolution over the first 50 years. Eur Heart J 34:2862–2872CrossRefPubMed
3.
Zurück zum Zitat Task Force on Myocardial Revascularization of the European Society of Cardiology, European Association for Cardio-Thoracic Surgery, European Association for Percutaneous Cardiovascular Interventions et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31:2501–2555CrossRef Task Force on Myocardial Revascularization of the European Society of Cardiology, European Association for Cardio-Thoracic Surgery, European Association for Percutaneous Cardiovascular Interventions et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31:2501–2555CrossRef
4.
Zurück zum Zitat Windecker S, Kolh P et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefPubMed Windecker S, Kolh P et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefPubMed
5.
Zurück zum Zitat Shahian DM, O’Brien SM, Filardo G et al (2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1 – coronary artery bypass grafting surgery. Ann Thorac Surg 88:S2–S22CrossRefPubMed Shahian DM, O’Brien SM, Filardo G et al (2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1 – coronary artery bypass grafting surgery. Ann Thorac Surg 88:S2–S22CrossRefPubMed
6.
Zurück zum Zitat Nashef SA, Roques F, Sharples LD et al (2012) EuroSCORE II. Eur J Cardiothorac Surg 41:734–745CrossRefPubMed Nashef SA, Roques F, Sharples LD et al (2012) EuroSCORE II. Eur J Cardiothorac Surg 41:734–745CrossRefPubMed
7.
Zurück zum Zitat Sianos G, Morel MA, Kappetein AP et al (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1:219–227PubMed Sianos G, Morel MA, Kappetein AP et al (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1:219–227PubMed
8.
Zurück zum Zitat De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001CrossRefPubMed De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001CrossRefPubMed
9.
Zurück zum Zitat Palmerini T, Benedetto U, Biondi-Zoccai G et al (2015) Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 65:2496–2507CrossRefPubMed Palmerini T, Benedetto U, Biondi-Zoccai G et al (2015) Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 65:2496–2507CrossRefPubMed
10.
Zurück zum Zitat Tada T, Byrne RA, Simunovic I et al (2013) Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 6:1267–1274CrossRefPubMed Tada T, Byrne RA, Simunovic I et al (2013) Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 6:1267–1274CrossRefPubMed
11.
Zurück zum Zitat Cassese S, Byrne RA, Tada T et al (2014) Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 100:153–159CrossRefPubMed Cassese S, Byrne RA, Tada T et al (2014) Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 100:153–159CrossRefPubMed
12.
Zurück zum Zitat Cassese S, Byrne RA, Ndrepepa G et al (2015) Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. doi:10.1016/S0140-6736(15)00979-4 PubMed Cassese S, Byrne RA, Ndrepepa G et al (2015) Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. doi:10.​1016/​S0140-6736(15)00979-4 PubMed
13.
Zurück zum Zitat Byrne RA, Kastrati A (2015) Bioresorbable drug-eluting stents: an immature technology in need of mature application. JACC Cardiovasc Interv 8:198–200CrossRefPubMed Byrne RA, Kastrati A (2015) Bioresorbable drug-eluting stents: an immature technology in need of mature application. JACC Cardiovasc Interv 8:198–200CrossRefPubMed
14.
Zurück zum Zitat Siontis GC, Stefanini GG, Mavridis D et al (2015) Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 386:655–664CrossRefPubMed Siontis GC, Stefanini GG, Mavridis D et al (2015) Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 386:655–664CrossRefPubMed
15.
Zurück zum Zitat Head SJ, Davierwala PM, Serruys PW et al (2014) Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J 35:2821–2830CrossRefPubMed Head SJ, Davierwala PM, Serruys PW et al (2014) Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J 35:2821–2830CrossRefPubMed
16.
Zurück zum Zitat Velazquez EJ, Lee KL, Jones RH et al (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374:1511–1520CrossRefPubMedPubMedCentral Velazquez EJ, Lee KL, Jones RH et al (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374:1511–1520CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Shaw LJ, Berman DS, Picard MH et al (2014) Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 7:593–604CrossRefPubMedPubMedCentral Shaw LJ, Berman DS, Picard MH et al (2014) Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 7:593–604CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Neumann FJ, Cremer J, Falk V, Reifart N, Silber S, Thielmann M (2012) Kommentar zu den gemeinsamen „Guidelines on myocardial revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS). Kardiologe 6:94–104CrossRef Neumann FJ, Cremer J, Falk V, Reifart N, Silber S, Thielmann M (2012) Kommentar zu den gemeinsamen „Guidelines on myocardial revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS). Kardiologe 6:94–104CrossRef
19.
Zurück zum Zitat Windecker S, Stortecky S, Stefanini GG et al (2014) Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 348:g3859CrossRefPubMedPubMedCentral Windecker S, Stortecky S, Stefanini GG et al (2014) Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 348:g3859CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Serruys PW, Morice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961–972CrossRefPubMed Serruys PW, Morice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961–972CrossRefPubMed
21.
Zurück zum Zitat Schomig A, Dibra A, Windecker S et al (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50:1373–1380CrossRefPubMed Schomig A, Dibra A, Windecker S et al (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50:1373–1380CrossRefPubMed
22.
Zurück zum Zitat Kapoor JR, Gienger AL, Ardehali R et al (2008) Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv 1:483–491CrossRefPubMed Kapoor JR, Gienger AL, Ardehali R et al (2008) Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv 1:483–491CrossRefPubMed
23.
Zurück zum Zitat Hannan EL, Zhong Y, Walford G et al (2014) Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. J Am Coll Cardiol 64:2717–2726CrossRefPubMed Hannan EL, Zhong Y, Walford G et al (2014) Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. J Am Coll Cardiol 64:2717–2726CrossRefPubMed
24.
Zurück zum Zitat Mohr FW, Morice MC, Kappetein AP et al (2013) Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5‑year follow-up of the randomised, clinical SYNTAX trial. Lancet 381:629–638CrossRefPubMed Mohr FW, Morice MC, Kappetein AP et al (2013) Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5‑year follow-up of the randomised, clinical SYNTAX trial. Lancet 381:629–638CrossRefPubMed
25.
Zurück zum Zitat Morice MC, Serruys PW, Kappetein AP et al (2014) Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation 129:2388–2394CrossRefPubMed Morice MC, Serruys PW, Kappetein AP et al (2014) Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation 129:2388–2394CrossRefPubMed
26.
Zurück zum Zitat Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C (2011) Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. J Am Coll Cardiol 58:1426–1432CrossRefPubMed Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C (2011) Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. J Am Coll Cardiol 58:1426–1432CrossRefPubMed
27.
Zurück zum Zitat Campos CM, van Klaveren D, Farooq V et al (2015) Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. Eur Heart J 36:1231–1241CrossRefPubMed Campos CM, van Klaveren D, Farooq V et al (2015) Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. Eur Heart J 36:1231–1241CrossRefPubMed
28.
Zurück zum Zitat Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL (2015) Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med 372:1213–1222CrossRefPubMed Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL (2015) Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med 372:1213–1222CrossRefPubMed
29.
Zurück zum Zitat Park SJ, Ahn JM, Kim YH et al (2015) Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 372:1204–1212CrossRefPubMed Park SJ, Ahn JM, Kim YH et al (2015) Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 372:1204–1212CrossRefPubMed
30.
Zurück zum Zitat Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384CrossRefPubMed Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384CrossRefPubMed
31.
Zurück zum Zitat Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF (2013) Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc 2:e000354CrossRefPubMedPubMedCentral Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF (2013) Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc 2:e000354CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Steg PG, Bhatt DL, Hamm CW et al (2013) Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382:1981–1992CrossRefPubMed Steg PG, Bhatt DL, Hamm CW et al (2013) Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382:1981–1992CrossRefPubMed
33.
Zurück zum Zitat Cassese S, Byrne RA, Tada T, King LA, Kastrati A (2012) Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 33:3078–3087CrossRefPubMed Cassese S, Byrne RA, Tada T, King LA, Kastrati A (2012) Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 33:3078–3087CrossRefPubMed
34.
Zurück zum Zitat Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166CrossRefPubMedPubMedCentral Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Palmerini T, Benedetto U, Bacchi-Reggiani L et al (2015) Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385:2371–2382CrossRefPubMed Palmerini T, Benedetto U, Bacchi-Reggiani L et al (2015) Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385:2371–2382CrossRefPubMed
36.
Zurück zum Zitat Roffi M, Patrono C et al (2015) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267–315CrossRefPubMed Roffi M, Patrono C et al (2015) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267–315CrossRefPubMed
37.
Zurück zum Zitat Frobert O, Lagerqvist B, Olivecrona GK et al (2013) Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369:1587–1597CrossRefPubMed Frobert O, Lagerqvist B, Olivecrona GK et al (2013) Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369:1587–1597CrossRefPubMed
38.
Zurück zum Zitat Jolly SS, Cairns JA, Yusuf S et al (2015) Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372:1389–1398CrossRefPubMedPubMedCentral Jolly SS, Cairns JA, Yusuf S et al (2015) Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372:1389–1398CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Engstrom T, Kelbaek H, Helqvist S et al (2015) Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet 386:665–671CrossRefPubMed Engstrom T, Kelbaek H, Helqvist S et al (2015) Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet 386:665–671CrossRefPubMed
40.
Zurück zum Zitat Gershlick AH, Khan JN, Kelly DJ et al (2015) Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 65:963–972CrossRefPubMedPubMedCentral Gershlick AH, Khan JN, Kelly DJ et al (2015) Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 65:963–972CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Wald DS, Morris JK, Wald NJ et al (2013) Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 369:1115–1123CrossRefPubMed Wald DS, Morris JK, Wald NJ et al (2013) Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 369:1115–1123CrossRefPubMed
42.
Zurück zum Zitat Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367:1287–1296CrossRefPubMed Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367:1287–1296CrossRefPubMed
43.
Zurück zum Zitat Patel MR, Smalling RW, Thiele H et al (2011) Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA 306:1329–1337CrossRefPubMed Patel MR, Smalling RW, Thiele H et al (2011) Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA 306:1329–1337CrossRefPubMed
44.
Zurück zum Zitat Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015CrossRefPubMed Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015CrossRefPubMed
45.
Zurück zum Zitat Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRefPubMed Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRefPubMed
46.
Zurück zum Zitat Montalescot G, Bolognese L, Dudek D et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369:999–1010CrossRefPubMed Montalescot G, Bolognese L, Dudek D et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369:999–1010CrossRefPubMed
47.
Zurück zum Zitat Montalescot G, van’t Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027CrossRefPubMed Montalescot G, van’t Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027CrossRefPubMed
48.
Zurück zum Zitat Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800CrossRefPubMed Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800CrossRefPubMed
Metadaten
Titel
Kommentar zu den „2014 ESC/EACTS Guidelines on Myocardial Revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS)
verfasst von
Prof. Dr. A. Kastrati
S. Baldus
J. Cremer
V. Falk
C. W. Hamm
F.-J. Neumann
H. Schunkert
A. Welz
Publikationsdatum
18.11.2016
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 6/2016
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-016-0106-0

Weitere Artikel der Ausgabe 6/2016

Der Kardiologe 6/2016 Zur Ausgabe

Passend zum Thema

ANZEIGE

SGLT-2-Inhibitoren für alle Patient:innen mit chronischer Herzinsuffizienz empfohlen

Das ESC-Leitlinien-Update 2023 bedeutet einen Paradigmenwechsel in der Behandlung der Herzinsuffizienz (HF), denn nun werden SGLT-2i sowohl für HFrEF, als auch für HFmrEF und HFpEF empfohlen. Somit können jetzt alle Patient:innen mit HF von SGLT-2i als zentralem Bestandteil der Therapie profitieren.

ANZEIGE

Dapagliflozin als neue Therapieoption zur Behandlung einer Herzinsuffizienz unabhängig von der Ejektionsfraktion

Dapagliflozin ist nun zur Behandlung aller Patient:innen mit chronischer symptomatischer Herzinsuffizienz zugelassen und bietet somit auch neue Hoffnung für die Therapie von jenen mit HFpEF. In der DELIVER-Studie zeigte der SGLT-2-Inhibitor eine signifikante Reduktion von Herzinsuffizienz-Hospitalisierungen und CV-Todesfällen.

ANZEIGE

ACS-Erstlinientherapie: Konsensbeschluss rät zur DAPT mit Ticagrelor

Ein Konsortium führender Fachgesellschaften erarbeitete jüngst auf Basis umfangreicher Metaanalysen einen Konsens für die Therapie koronarer Herzkrankheiten. Was dabei auffiel: Die duale Plättchenhemmung (DAPT) mit Ticagrelor ist die bevorzugte Therapieoption für das akute Koronarsyndrom (ACS).